Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series.

J Cachexia Sarcopenia Muscle · 2023 · PMC10570071 · PMID 37671529

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

likely to be significantno p-value reported

Within studies, there were also likely to be significant individual patient differences and there may be an assumption that the cancer is causing weight loss, reduced function and loss of lean mass when it is possible that it may be multifactorial.

also in 279 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.